Skyrizi 150 mg/mL (Risankizumab-Rzaa INJECTION) 150 mg/mL

Skyrizi 150 mg/mL is a subcutaneous injection used for managing moderate to severe plaque psoriasis. This medication, containing risankizumab-rzaa, is designed to help reduce inflammation and improve skin condition.

Strength

150 mg/mL

Pack Size

1 SYRINGE in 1 CARTON (0074-2100-70) / 1 mL in 1 SYRINGE

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Skyrizi 150 mg/mL is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. This medication works by targeting specific proteins in the body to reduce inflammation and promote skin healing. People often ask, 'What is Skyrizi used for?' and the answer is that it is intended for those who have not responded well to other treatments or have severe symptoms.

Side Effects

Common effects of Skyrizi 150 mg/mL may include redness, itching, or swelling at the injection site. Some individuals might experience fatigue, headache, or upper respiratory infections. These effects vary and are not experienced by everyone. It's important to monitor any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Skyrizi 150 mg/mL should be handled with care, ensuring proper storage and administration as directed. It is important to inform your healthcare provider about any allergies or medical conditions before starting this treatment. Always follow the prescribed guidelines for subcutaneous injections to minimize risks.

Avoid Interactions

Skyrizi 150 mg/mL may interact with other medications, including those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness or safety of this treatment.

Frequently Asked Questions

Skyrizi 150 mg/mL is used for the treatment of moderate to severe plaque psoriasis in adults.

Skyrizi 150 mg/mL is administered via subcutaneous injection, typically self-administered or by a healthcare provider.

Common side effects may include redness, itching, or swelling at the injection site, as well as fatigue and headache.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Skyrizi 150 mg/mL should be stored as directed, typically in a refrigerator, to maintain its effectiveness.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.